Michael E. Hurwitz

Also affiliated with Yale University, University of New Haven

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.448Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

Papers

Driven by 21 papers — median percentile 58. Top paper: “A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better”.

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Molecular Cancer(2023)10.1186/s12943-023-01884-x

N/A

0.635DataRank · unranked

14 citations

Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi +18 more

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma

JCI Insight(2024)10.1172/jci.insight.184545

N/A

0.466DataRank · unranked

14 citations

Dijana Djureinovic, David Su, Lin Zhang, Benjamin Y. Lu, Larisa Kamga +8 more

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO Open(2025)10.1016/j.esmoop.2024.104105

Top 42%

0.448DataRank

Top 42%11 citations

G. G. Birch, Alia Meliki, V Moritz, Mausumi Bharadwaj, Nicholas R. Schindler +20 more

TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3

Cancer Immunology Immunotherapy(2024)10.1007/s00262-024-03773-8

N/A

0.208DataRank · unranked

3 citations

Lucia B. Jilaveanu, Adebowale Adeniran, David Su, Michael E. Hurwitz, David A. Braun +3 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.28

N/A

0DataRank · unranked

2 citations

Jessica B. Long, Sarah J. Westvold, Stephanie B. Wheeler, Lisa P. Spees, Michael Leapman +5 more

Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.610

N/A

0DataRank · unranked

0 citations

Jessica B. Long, Sirad Hassan, Stephanie B. Wheeler, Lisa P. Spees, Michael Leapman +5 more

Data from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

(2023)10.1158/1078-0432.c.6530444

N/A

0DataRank · unranked

0 citations

Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia B. Jilaveanu +17 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.8747

N/A

0DataRank · unranked

3 citations

Jessica B. Long, Sarah J. Westvold, Michael Leapman, Lisa P. Spees, Michael E. Hurwitz +5 more

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae067

N/A

0DataRank · unranked

1 citations

Jessica B. Long, Sarah J. Westvold, Khushi Agnish, Hannah D. McManus, Michael Leapman +6 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012358

N/A

0DataRank · unranked

4 citations

Noam Savion‐Gaiger, Ana Luisa Perdigoto, Jacqueline E. Mann, Madeline Candelas Torres, Genevieve M. Boland +12 more

Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients

Frontiers in Endocrinology(2025)10.3389/fendo.2025.1697724

N/A

0DataRank · unranked

2 citations

Michael E. Hurwitz, Navid Hafez, Harriet M. Kluger, Kevan C. Herold, Ana Luisa Perdigoto +1 more

Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer(2025)10.1016/j.clgc.2025.102330

N/A

0DataRank · unranked

0 citations

Jessica B. Long, Sarah J. Westvold, Michael Leapman, Michael E. Hurwitz, Aaron Philip Mitchell +4 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function

Frontiers in Oncology(2022)10.3389/fonc.2022.836859

N/A

0DataRank · unranked

77 citations

Sarah A. Weiss, Matthew Austin, Amit Mahajan, Katrina Etts, Lin Zhang +7 more

Clonal Screens to Find Modifiers of Partially Penetrant Phenotypes in C. elegans

Methods in Molecular Biology(2014)10.1007/978-1-4939-0992-6_13

N/A

0DataRank · unranked

0 citations

Michael E. Hurwitz

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance

Frontiers in Oncology(2022)10.3389/fonc.2022.990367

N/A

0DataRank · unranked

20 citations

Ross D. Merkin, Myrto Moutafi, Sandra Martinez, Adebowale Adeniran, Deepika Kumar +5 more

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure

Molecular Cancer(2022)10.1186/s12943-022-01688-5

N/A

0DataRank · unranked

8 citations

Yuval Kluger, Junchen Yang, Jun Zhao, David A. Hafler, Diane S. Krause +6 more

Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma

JNCI Cancer Spectrum(2023)10.1093/jncics/pkad036

N/A

0DataRank · unranked

12 citations

Jessica B. Long, Sirad Hassan, Stephanie B. Wheeler, Lisa P. Spees, Michael Leapman +5 more

Michael E. Hurwitz

Indexed papers

Top data-sharing exemplar

Papers